慢性淋巴性白血病市場:KOL的洞察

本報告提供全球慢性淋巴性白血病市場相關調查，市場概要，以及已上市治療方法，開發平台趨勢，未來預測等資訊。

目錄

摘要整理

現在及未來的治療流程

調查目的

Breton型蛋白酪氨酸激梅(BTK)抑制劑/分解劑

• 已通過核准BTK抑制劑(46)
  • Ibruvica（依魯替尼、艾伯維/強生）
  • Calabrutinib（阿斯特捷利康）
  • Brukinsa（zanubrutinib、百濟神州）
  • Japirka（piltobrutinib，禮來公司）
• 開發平台(管線)BTK抑制劑及分解劑
  • nemutaburuchinibu(Merck & Co.)
  • NX-5948，NX-2127(Nurix Therapeutics)及BGB-16673(BeiGene)

Bcl-2抑制劑

• 已通過核准治療方法
  • Venclexta/Venclyxt（Venetoclax、艾伯維/羅氏）
• 開發平台(管線)療法
  • Sonrotoclax（BGB-11417；百濟神州）和 Risaftoclax（亞盛醫藥）

CAR T細胞療法

• 開發平台(管線)醫藥品
  • Brayange（Lysocabtagen Malaleucel、百時美施貴寶）
  • MB-106(Mustang Bio)

雙特異性抗體

• 開發平台(管線)醫藥品
  • Epkinley/Tepkinley（epcolitamab、AbbVie/Genmab）和 Colombi（grofitamab、羅氏）

今後的治療趨勢

• 主要的洞察摘要

附錄

How do the experts see the potential for fixed-duration combination treatments playing out in first-line CLL therapy? Why do KOLs say AstraZeneca's Calquence + AbbVie/Roche's Venclexta combination is important? What opportunities lie ahead for BeiGene's Brukinsa? How do KOLs assess the potential of BTK degraders such as Nurix's NX-5948 and BeiGene's BGB-16673? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary (11)

Current and future treatment algorithm

Research objectives (2)

Bruton's tyrosine kinase (BTK) inhibitors/degraders (66)

• Approved BTK inhibitors (46)
  • Imbruvica (ibrutinib; AbbVie/J&J) (11)
  • Calquence (acalabrutinib; AstraZeneca) (11)
  • Brukinsa (zanubrutinib; BeiGene) (9)
  • Jaypirca (pirtobrutinib; Lilly) (15)
• Pipeline BTK inhibitors and degraders (20)
  • Nemtabrutinib (Merck & Co.) (10)
  • NX-5948, NX-2127 (Nurix Therapeutics) & BGB-16673 (BeiGene) (10)

Bcl-2 inhibitors (19)

• Approved therapies (10)
  • Venclexta/Venclyxto (venetoclax; AbbVie/Roche) (10)
• Pipeline therapies (9)
  • Sonrotoclax (BGB-11417; BeiGene) and lisaftoclax (Ascentage Pharma) (9)

CAR T-cell therapies (16)

• Pipeline drugs (16)
  • Breyanzi (lisocabtagene maraleucel; Bristol Myers Squibb) (11)
  • MB-106 (Mustang Bio) (5)

Bispecific antibodies (8)

• Pipeline drugs (8)
  • Epkinly/Tepkinly (epcoritamab; AbbVie/Genmab) and Columvi (glofitamab; Roche) (8)

Future treatment trends (5)

• Key insights summary (5)

Appendix (4)

• KOL details (4)
  • KOLs from North America (1)
  • KOLs from Europe (2)